Edition:
United States

Idorsia Ltd (IDIA.S)

IDIA.S on Swiss Exchange

16.72CHF
18 Jan 2019
Change (% chg)

CHF0.23 (+1.39%)
Prev Close
CHF16.49
Open
CHF16.70
Day's High
CHF16.89
Day's Low
CHF16.57
Volume
233,151
Avg. Vol
335,565
52-wk High
CHF30.70
52-wk Low
CHF15.20

Chart for

About

Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including... (more)

Overall

Beta: --
Market Cap(Mil.): CHF2,096.57
Shares Outstanding(Mil.): 119.12
Dividend: --
Yield (%): --

Financials

  IDIA.S Industry Sector
P/E (TTM): -- 69.71 33.71
EPS (TTM): -- -- --
ROI: -- 8.99 14.48
ROE: -- 10.13 15.99

BRIEF-Idorsia Starts Multiple-Dose Efficacy And Safety Study With Cenerimod For Treatment Of Systemic Lupus Erythematosus

* IDORSIA INITIATES A MULTIPLE-DOSE EFFICACY AND SAFETY STUDY WITH CENERIMOD FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jan 07 2019

BRIEF-Idorsia's Selatogrel Phase 2 Clinical Studies Meet Their Objective

* IDORSIA'S P2Y12 RECEPTOR ANTAGONIST - SELATOGREL - PHASE 2 CLINICAL STUDIES MEET THEIR OBJECTIVE

Dec 18 2018

BRIEF-Idorsia Maintains Collaboration Agreement With Reveragen

* FOLLOWING RECEIPT OF CLINICAL STUDY REPORT FOR PHASE 2A STUDY WITH VAMOROLONE, WILL PAY REVERAGEN USD 15 MILLION TO MAINTAIN AGREEMENT Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Nov 05 2018

BRIEF-Idorsia Says Representative Of Former Axovan Shareholders Filed Complaint Against Actelion

* SAYS REPRESENTATIVE OF FORMER AXOVAN SHAREHOLDERS CLAIMS DEMERGER OF ACTELION AND IDORSIA WOULD TRIGGER ACCELERATION OF ALL OUTSTANDING MILESTONE PAYMENTS FOR CLAZOSENTAN

Oct 24 2018

BRIEF-Idorsia 9Mth US GAAP Net Loss Of CHF 278 Mln

* US GAAP OPERATING RESULTS IN 9M 2018: LOSS OF CHF 271 MILLION

Oct 23 2018

BRIEF-Idorsia H1 US GAAP Net Loss At CHF 159 Mln

* US GAAP OPERATING RESULTS IN HY 2018: LOSS OF CHF 155 MILLION

Jul 24 2018

Earnings vs. Estimates